Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
The STEP 1 trial reported an average body-weight reduction of 14.9% with branded injectable semaglutide 2.4 mg over 68 weeks
Toujeo specifically enters the picture when a patient needs basal insulin and either has already tried and failed GLP-1 therapy, has a contraindication to GLP-1 drugs, has Type 1 diabetes, or has very advanced Type 2 diabetes with negligible beta cell function
That is why endocrine therapies such as tamoxifen and aromatase inhibitors are so important for hormone receptor-positive disease
Looking ahead, the drug pricing will continue to compress with direct-to-consumer programs, innovative pricing models and the approval of oral GLP-1 medications, all likely to influence market dynamics over the next few years
PlexusDx patients receiving compounded semaglutide injections experience the same elimination pattern as brand-name versions, ensuring predictable timelines regardless of source
